Successful Cetuximab Therapy After Failure of Panitumumab Rechallenge in a Patient with Metastatic Colorectal Cancer: Restoration of Drug Sensitivity After Anti-EGFR Monoclonal Antibody-Free Interval

摘要

We previously reported the efficacy of panitumumab rechallenge for chemorefractory metastatic colorectal cancer (mCRC) [1]. Interestingly, cetuximab combination therapy was also effective after the failure of panitumumab rechallenge in the present case. Anti-epidermal growth factor receptor (EGFR) monoclonal antibody (MoAb) exerted clinical benefit three times, due to anti-EGFR MoAb-free intervals. We herein describe the clinical course following the failure of panitumumab rechallenge.